Table 1.
Baseline characteristics of included patients in residential care facilities (n = 58)
| Demographics and baseline parameters | No. of residents (%) |
|---|---|
| Sex | |
| Female | 44 (75.9) |
| Male | 14 (24.1) |
| Age (years) | |
| 40‐49 | 1 (1.7) |
| 50‐59 | 2 (3.4) |
| 60‐69 | 4 (6.9) |
| 70‐79 | 6 (10.3) |
| 80‐89 | 16 (27.6) |
| 90‐99 | 29 (50.0) |
| PPI indication | |
| GI bleed | 6 (10.3) |
| Gastroesophageal reflux disease | 6 (10.3) |
| Dysphagia/nausea/emesis | 5 (8.6) |
| GI condition (e.g, diverticulitis, ulcerations) | 4 (6.9) |
| Stomach protectant for concomitant drug use (e.g, NSAIDs, DOACs) | 2 (3.4) |
| Likely indication | 21 (36.2) |
| Unknown | 14 (24.1) |
| PPI use (total daily dose)* | |
| Pantoprazole | |
| 20 mg once daily | 7 (12.1) |
| 20 mg twice daily | 1 (1.7) |
| 40 mg once daily | 25 (43.1) |
| 40 mg twice daily | 6 (10.3) |
| 40 mg as needed | 1 (1.7) |
| Esomeprazole | |
| 20 mg once daily | 2 (3.4) |
| 20 mg twice daily | 1 (1.7) |
| 40 mg once daily | 15 (25.9) |
*Correction added on 16 May 2019, after first online publication: The subheading has been changed from 'totally daily base' to 'total daily dose'.
Abbreviations: DOACs, direct oral anticoagulants; GI, gastrointestinal; PPI, proton pump inhibitor.